CellSeed Inc.
Research CellSeed Inc. (7776.T) on Bullrun: market cap JPY 8.12B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7776.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 8.12B
- Financial periodFY2025
- RevenueJPY 83.68M
- Revenue growth-56.7%
- Net income-JPY 1.10B
- Free cash flow-JPY 1.02B
- Gross margin51.1%
Valuation Snapshot
latest market cap is JPY 8.12B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 83.68M | -JPY 1.10B | -JPY 1.02B | 51.1% | -31.82 | JPY 1.32B | JPY 132.92M | JPY 1.27B |
| FY2024 | JPY 193.28M | -JPY 859.84M | -JPY 884.47M | 57.0% | -25.72 | JPY 2.13B | JPY 143.75M | JPY 2.16B |
| FY2023 | JPY 190.13M | -JPY 846.53M | -JPY 801.07M | 56.4% | -29.43 | JPY 2.16B | JPY 151.25M | JPY 2.16B |
| FY2022 | JPY 126.43M | -JPY 759.68M | -JPY 733.60M | 48.3% | -36.31 | JPY 1.07B | JPY 158.75M | JPY 1.18B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 8.12B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About CellSeed Inc.
CellSeed Inc. engages in the cell sheet regenerative medicine business in Japan, the rest of Asia, and Europe. It operates through Regenerative Medicine Support Business and Cell Sheet Regenerative Medicine Business segments. The company is involved in commercializing regenerative medicine using cell sheets, which include autologous and allogeneic chondrocyte sheets. It also offers regenerative medicine contract services comprising contract development and manufacturing;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is CellSeed Inc.'s market cap?
CellSeed Inc.'s market capitalization is JPY 8.12B.
What does CellSeed Inc. do?
CellSeed Inc. engages in the cell sheet regenerative medicine business in Japan, the rest of Asia, and Europe. It operates through Regenerative Medicine Support Business and Cell Sheet Regenerative Medicine Business segments. The company is involved in commercializing regenerative medicine using cell sheets, which include autologous and allogeneic chondrocyte sheets.